



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/667,004

09/19/2003

Selena Chan

070702006420

6646

7590

10/30/2006

Raj S. Dave
Morrison & Foerster LLP
Suite 300
1650 Tysons Blvd.
McLean, VA 22102

EXAMINER

LU, FRANK WEI MIN

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 10/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/667,004

Applicant(s)

CHAN ET AL.

Examiner

Frank W. Lu

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 August 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-28 is/are pending in the application.
- 4a) Of the above claim(s) 25-28 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 19 September 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Response to Amendment

1. Applicant's response to the office action filed on August 17, 2006 has been entered. The claims pending in this application are claims 1-28 wherein claims 25-28 have been withdrawn due to restriction requirements. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the response filed on August 17, 2006.

Election/Restrictions

2. This application contains claims 25-28 drawn to an invention nonelected without traverse. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 11, 13, 14, 21, and 24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

5. Claim 11 or 21 is rejected as vague and indefinite because force modulation imaging and magnetoresistive sensitivity mapping are not scanning probe microscopy. Please clarify.

6. Claim 13 is rejected as vague and indefinite because it is unclear what means "determining sequences of oligonucleotides that bind to the". Please clarify.

Art Unit: 1634

7. Claim 24 is rejected as vague and indefinite. Since step c) of claim 19 requires aligning on a surface the coded probes that bind to the one or more target molecules while claim 24 requires separating the bound coded probes from all target molecules before the coded probes are aligned on a surface, if the bound coded probes are separated from all target molecules before the coded probes are aligned on a surface as recited in claim 24, it is unclear how to align on a surface the coded probes that bind to the one or more target molecules. Therefore, claims 19 and 24 do not correspond each other. Please clarify.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 1-6, 9, and 15-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mirkin *et al.*, (US Patent No. 6,984,491 B1, filed on December 7, 2001).

Art Unit: 1634

Regarding claims 1-3, 6, 15, and 16, since Mirkin *et al.*, teach to hybridize SEQ ID NO: 33 immobilized on a nanoparticle which is on a substrate to a linking oligonucleotide comprising SEQ ID NO: 34, and then hybridize a complex formed by SEQ ID NO: 33 and the linking oligonucleotide comprising SEQ ID NO: 34 to SEQ ID NO: 35 immobilized on a nanoparticle (see Example 6 in columns 85 and 86, and Figure 13B), Mirkin *et al.*, disclose obtaining a plurality of coded probes (eg., SEQ ID NO:33 and SEQ ID NO:35), each coded probe comprising a probe molecule attached to at least one nanobarcode (ie., nanoparticle), contacting a target molecule (eg., the linking oligonucleotide comprising SEQ ID NO: 34) with the coded probes, and arranging the coded probes that bind to the one or more target molecules (ie., forming nanoparticle aggregates linked to substrate by analyte DNA) as recited in steps a) to c) of claim 1 wherein each coded probe comprises an oligonucleotide as recited in claim 2, the target molecule is a nucleic acid as recited in claim 3 or 16, the nucleic acid is attached to a surface as recited in claim 6, and identifying the nucleic acid from the coded oligonucleotide probes that bind to the nucleic acid as recited in claim 15. Since Mirkin *et al.*, teach to identify hybridization complex formed by SEQ ID NOs: 33-35 by UV-vis absorbance (see columns 85 and 86 and Figure 14A), Mirkin *et al.*, disclose identifying the organized coded probes and detecting one or more the target molecules based on the bound coded probes (ie., detecting the hybridization between the target molecule and the coded probes) as steps d) and e) of claim 1. Although Mirkin *et al.*, do not teach to use different sized gold nanoparticles in example 6 (see columns 85 and 86), since Mirkin *et al.*, teach to label different probes with different sized gold nanoparticles in order to scatter light of different colors (see column 25, lines 45-63), in view of the teachings of Mirkin *et al.*, it is obvious to one having ordinary skill in the art at the time the

Art Unit: 1634

invention was made to use at least two of the coded probes comprising identifiably different nano-barcodes (ie., nano-particles) as recited in step a) of claim 1.

Regarding claims 4 and 5, Mirkin *et al.*, teach that a library of coded probes comprising all possible sequences for a particular length of oligonucleotide is contacted with the target molecule as recited in claim 4 wherein the nanobarcode is nanoparticles as recited in claim 5 (see Figures 17A to 17C).

Regarding claim 9, Mirkin *et al.*, teach further comprising aligning the coded probes on a surface by molecular combing as recited in claim 9 (see Figure 21).

Regarding claims 17 and 18, since the target nucleic acid used in the assay taught by Mirkin *et al.*, comprises multiple identical molecules, Mirkin *et al.*, teach further that two or more target molecules are present in a sample and all target molecules in the sample are analyzed at the same time as recited in claim 17 and two or more target molecules are present in a sample and all target molecules of the same kind are analyzed at the same time as recited in claim 18 (see Figures 20 B, 21 and 22).

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have performed the method recited in claim 1 wherein at least two of the coded probes comprise identifiably different nano-barcodes (ie., nano-particles) as recited in step a) of the claim in view of the patent of Mirkin *et al.*. One having ordinary skill in the art would have been motivated to do so because Mirkin *et al.*, teach to label different probes with different sized gold nanoparticles in order to scatter light of different colors (see column 25, lines 45-62). One having ordinary skill in the art at the time the invention was made

would have been a reasonable expectation of success to perform the method recited in claim 1 using at least two of the coded probes comprising identifiably different nano-barcodes (ie., nano-particles) in view of the patent of Mirkin *et al.*.

10. Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mirkin *et al.*, (2001) as applied to claims 1-6, 9, and 15-18 above, and further in view of Birkenmeyer *et al.*, (US Patent No. 5,427,930, published on June 27, 1995).

The teachings of Mirkin *et al.*, have been summarized previously, *supra*.

Mirkin *et al.*, do not disclose ligating adjacent coded oligonucleotide probes that are hybridized to the nucleic acid or target molecule and separating ligated coded oligonucleotide probes from the nucleic acid or target molecule and non-ligated coded oligonucleotide probes as recited in claims 7 and 8. However, since Mirkin *et al.*, teach to wash the substrate after each hybridization step (see columns 85 and 86), Mirkin *et al.*, teach separating the coded oligonucleotide probes from the nucleic acid and non-ligated coded oligonucleotide probes.

Birkenmeyer *et al.*, teach filling the gap between two adjacent probes when they are hybridized to a target nucleic acid and separating ligated probes from the target nucleic acid and non-ligated probes (see abstract and columns 2-4). Since Birkenmeyer *et al.*, teach ligating extended probe A to probe B, and extended probe B' to probe A', using said ligase reagent to form reorganized probe molecules, providing denaturing conditions to separate said reorganized probe molecules from said template and separating reorganized probe molecules from unreorganized labeled probes (see column 3), Birkenmeyer *et al.*, disclose claims 7 and 8.

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art

Art Unit: 1634

at the time the invention was made to have ligated adjacent coded oligonucleotide probes that are hybridized to the nucleic acid or target molecule and separated ligated coded oligonucleotide probes from the nucleic acid or target molecule and non-ligated coded oligonucleotide probes as recited in claims 7 and 8 in view of the patents of Mirkin *et al.*, and Birkenmeyer *et al.*. One having ordinary skill in the art would have been motivated to do so because Birkenmeyer *et al.*, have successfully filled the gap between two adjacent probes when they are hybridized to a target nucleic acid and separated ligated probes from the target nucleic acid and non-ligated probes (see abstract and columns 2-4), and Birkenmeyer *et al.*, suggest that filling the gap between two adjacent probes by a ligase chain reaction creates geometrically increasing numbers of reorganized probe molecules in the presence of said target sequence (see column 2, lines 51-58). One having ordinary skill in the art at the time the invention was made would have been a reasonable expectation of success to ligate adjacent coded probes that are hybridized to the nucleic acid in view of the patents of Mirkin *et al.*, and Birkenmeyer *et al.*.

11. Claims 10-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mirkin *et al.*, (2001) as applied to claims 1-6, 9, and 15-18 above, and further in view of Nygren *et al.*, (US Patent No. 6,060,237, filed on January 17, 1995).

The teachings of Mirkin *et al.*, have been summarized previously, *supra*.

Regarding claims 13 and 14, since Mirkin *et al.*, teach to use their method in sequencing nucleic acid (see column 40, lines 27-50), Mirkin *et al.*, must disclose or suggest further comprising determining the sequences of oligonucleotides that bind to the nucleic acid and further comprising determining the sequence of the nucleic acid from the sequences of

Art Unit: 1634

oligonucleotides that bind to the nucleic acid as recited in claims 13 and 14.

Mirkin *et al.*, do not disclose that the coded probes are identified by scanning probe microscopy as recited in claim 10 wherein the scanning probe microscopy is scanning tunneling as recited in claim 11 and wherein the coded probes aligned on the surface are identified by scanning probe microscopy as recited in claim 12. However, Mirkin *et al.*, teach to identify the coded probes by transmission electron microscopy (see column 78, lines 42-62) or fluorescence microscopy (see column 95, second paragraph).

Nygren *et al.*, teach to detect hybridization by scanning tunneling microscopy (see column 3, fourth paragraph).

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have identified the coded probes by scanning probe microscopy wherein the scanning probe microscopy is scanning tunneling microscopy as recited in claims 10-12 in view of the patents of Mirkin *et al.*, and Nygren *et al.*. One having ordinary skill in the art would have been motivated to do so because Nygren *et al.*, have successfully detected hybridization by scanning tunneling microscopy and the simple replacement of one well known detection method (i.e., the method taught by Mirkin *et al.*,) from another well known detection method (i.e., detecting hybridization by scanning tunneling microscopy taught by Nygren *et al.*,) during the process of performing the method recited in claims 10-12 would have been, in the absence of convincing evidence to the contrary, *prima facie* obvious to one having ordinary skill in the art at the time the invention was made because the detection method taught by Mirkin *et al.*, and the detection method taught by Nygren *et al.*, are two functional equivalent methods which are used for the same purpose (ie., detecting hybridization).

Art Unit: 1634

Furthermore, the motivation to make the substitution cited above arises from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. Support for making the obviousness rejection comes from the M.P.E.P. at 2144.06.

12. Claims 19-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mirkin *et al.*, (2001) as applied to claims 1-6, 9, and 15-18 above, and further in view of Nygren *et al.*, (US Patent No. 6,060,237, filed on January 17, 1995).

The teachings of Mirkin *et al.*, have been summarized previously, *supra*.

Regarding claim 19, since Mirkin *et al.*, teach to hybridize SEQ ID NO: 33 immobilized on a nanoparticle which is on a substrate to a linking oligonucleotide comprising SEQ ID NO: 34, and then hybridize a complex formed by SEQ ID NO: 33 and the linking oligonucleotide comprising SEQ ID NO: 34 to SEQ ID NO: 35 immobilized on a nanoparticle (see Example 6 in columns 85 and 86, and Figure 13B), Mirkin *et al.*, disclose obtaining a plurality of coded probes (eg., SEQ ID NO:33 and SEQ ID NO:35), each coded probe comprising a probe molecule attached to at least one nanobarcode (ie., nanoparticle), contacting a target molecule (eg., the linking oligonucleotide comprising SEQ ID NO: 34) with the coded probes, and wherein one or more coded probe bind to the target molecules; and aligning on a surface the coded probes that bind to the one or more target molecules (ie., forming nanoparticle aggregates linked to substrate by analyte DNA) as recited in steps a) to c) of claim 19. Since Mirkin *et al.*, teach to identify hybridization complex formed by SEQ ID NOs: 33-35 by UV-vis absorbance (see column 50 and Figure 14A), Mirkin *et al.*, disclose identifying the aligned coded probes and detecting one

Art Unit: 1634

or more the target molecules from the identified coded probes (ie., detecting the hybridization between the target molecule and the coded probes) as steps d) and e) of claim 19. Although Mirkin *et al.*, do not teach to use different sized gold nanoparticles in example 6 (see columns 85 and 86), since Mirkin *et al.*, teach to label different probes with different sized gold nanoparticles in order to scatter light of different colors (see column 25, lines 45-63), in view of the teachings of Mirkin *et al.*, it is obvious to one having ordinary skill in the art at the time the invention was made to use at least two of the coded probes comprising identifiably different nano-barcodes (ie., nano-particles) as recited in step a) of claim 19.

Regarding claims 20 and 22, since claims 3 and 9 are identical to claims 20 and 22 respectively, Mirkin *et al.*, teach claims 20 and 22.

Regarding claim 23, since claims 2, 13, and 14 includes all limitations recited in claim 23, Mirkin *et al.*, teach further comprising determining at least part of the sequence of the nucleic acid from the bound coded probes.

Mirkin *et al.*, do not disclose that the aligned coded probes are identified by scanning probe microscopy as recited in step d) of claim 19 wherein the scanning probe microscopy is scanning tunneling as recited in claim 21. However, Mirkin *et al.*, teach to identify the coded probes by transmission electron microscopy (see column 78, lines 42-62) or fluorescence microscopy (see column 95, second paragraph).

Nygren *et al.*, teach to detect hybridization by scanning tunneling microscopy (see column 3, fourth paragraph).

Art Unit: 1634

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have identified the aligned coded probes by scanning probe microscopy wherein the scanning probe microscopy is scanning tunneling microscopy as recited in claims 19 and 21 in view of the patents of Mirkin *et al.*, and Nygren *et al.*. One having ordinary skill in the art would have been motivated to do so because Nygren *et al.*, have successfully detected hybridization by scanning tunneling microscopy and the simple replacement of one well known detection method (i.e., the method taught by Mirkin *et al.*,) from another well known detection method (i.e., detecting hybridization by scanning tunneling microscopy taught by Nygren *et al.*,) during the process of performing the method recited in claims 19 and 21 would have been, in the absence of convincing evidence to the contrary, *prima facie* obvious to one having ordinary skill in the art at the time the invention was made because the detection method taught by Mirkin *et al.*, and the detection method taught by Nygren *et al.*, are two functional equivalent methods which are used for the same purpose (ie., detecting hybridization).

Furthermore, the motivation to make the substitution cited above arises from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. Support for making the obviousness rejection comes from the M.P.E.P. at 2144.06.

Response to Arguments

Applicant's arguments with respect to claims 1-23 (see page 9, third paragraph bridging to page 10, second paragraph of applicant's remarks) have been considered but are moot in view of the new ground(s) of rejection.

Double Patenting

13. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

14. Claims 1-23 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4, 5, 9-15, 17, 18, and 28-31 of copending Application No. 10/251,152. Although the conflicting claims are not identical, they are not patentably distinct from each other because an obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but examined claims in this instant application are not patentably distinct from the reference claims because the examined claims are either anticipated by, or would have been obvious over, the reference claims. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761

Art Unit: 1634

(CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). Although claims 1-23 in this instant application are not identical to claims 1, 4, 5, 9-15, 17, 18, and 28-31 of copending Application No. 10/251,152, claims 1, 4, 5, 9-15, 17, 18, and 28-31 of copending Application No. 10/251,152 are directed to the same subject matter and fall entirely within the scope of claims 1-23 in this instant application. In other words, claims 1-23 in this instant application are anticipated by claims 1, 4, 5, 9-15, 17, 18, and 28-31 of copending Application No. 10/251,152.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

In page 10, third paragraph of applicant's remarks, applicant argues that "[T]he Examiner has provisionally rejected claim 1-23 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4, 5, 9-15, 17, 18, and 28-31 of copending Application No. 10/251,152. Applicants acknowledge this rejection, but since it is only provisional no action is required at this time".

This argument has been fully considered but it is not persuasive toward the withdrawal of the rejection because applicant does not file a terminal disclaimer to overcome this rejection.

Conclusion

15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

16. No claim is allowed.

17. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

October 19, 2006


FRANK LU
PRIMARY EXAMINER